Use of Metabolic Inert Mycobacterium abscessus Cells to Study the Efficiency Of Drugs

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

We investigated the effectiveness of antibiotics (amikacin, bedaquiline, linezolid, moxifloxacin, rifampicin) on metabolically inert M. abscessus obtained under conditions of potassium deficiency in vitro. It was found that bedaquiline led to a significant decrease in the ability of bacteria to form colonies on solid media, but did not lead to their death, since it was shown that during cultivation in a liquid medium, they reverted to a state of active division and growth. Moxifloxacin had a bactericidal effect against metabolically inert bacteria, irreversibly and significantly reducing the number of viable cells in culture, which emphasizes the effectiveness of its use for the treatment of infections caused by M. abscessus.

作者简介

B. Martini

A.N. Bach Institute of Biochemistry, Research Center of Biotechnologies Russian Academy of Sciences

Email: elenasalina@yandex.ru
Russia, 119071, Moscow

E. Salina

A.N. Bach Institute of Biochemistry, Research Center of Biotechnologies Russian Academy of Sciences; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

编辑信件的主要联系方式.
Email: elenasalina@yandex.ru
Russia, 119071, Moscow; Russia, 117997, Moscow

参考

  1. Johansen M.D., Herrmann J.L., Kremer L. // Nat. Rev. Microbiol. 2020. V. 18. № 1. P. 392–407. https://doi.org/10.1038/s41579-020-0331-1
  2. Recchia D., Stelitano G., Stamilla A., Gutierrez D.L., Degiacomi G., Chiarelli L.R., Pasca M.R. // Int. J. Mol. Sci. 2023. V. 24. № 5. P. 4635. https://doi.org/10.3390/ijms24054635
  3. Sepulcri C., Vena A., Bassetti M. // Curr. Opin. Infect. Dis. 2023. V. 36. № 2. P. 74–80. https://doi.org/10.1097/QCO.0000000000000905
  4. Berube B.J., Castro L., Russell D., Ovechkina Y., Parish T. // Front Microbiol. 2018. V. 9. P. 2417. https://doi.org/10.3389/fmicb.2018.02417
  5. Yam Y.K., Alvarez N., Go M.L., Dick T. // Front Microbiol. 2020. V. 11. P. 359. https://doi.org/10.3389/fmicb.2020.00359
  6. Shleeva M., Mukamolova G.V., Young M., Williams H.D., Kaprelyants A.S. // Microbiology. 2004. V. 150. P. 1687–1697. https://doi.org/10.1099/mic.0.26893-0
  7. Salina E.G., Waddell S.J., Hoffmann N., Rosenkrands I., Butcher P.D., Kaprelyants A.S. // Open Biol. 2014. V. 4. P. 140106. https://doi.org/10.1098/rsob.140106
  8. Connell N. // Methods Cell Biol. 1994. V. 45 P. 107–125. https://doi.org/10.1016/s0091-679x(08)61848-8
  9. Shleeva M.O., Kudykina Y.K., Vostroknutova G.N., Suzina N.E., Mulyukin A.L., Kaprelyants A.S. // Tuberculosis (Edinb). 2011. V. 91. P. 146–154. https://doi.org/10.1016/j.tube.2010.12.006
  10. de Man J.C. // J. Appl. Microbiol. 1975. V. 1. P. 67–78. https://doi.org/10.1007/BF01880621
  11. Palomino J.C., Martin A., Camacho M., Guerra H., Swings J., Portaels F. // Antimicrob. Agents Chemother. 2002. V. 46. № 8. P. 2720–2722. https://doi.org/10.1128/AAC.46.8.2720-2722.2002
  12. Coban A.Y., Deveci A., Sunter A.T., Palomino J.C., Martin A. // Int J Mycobacteriol. 2014. V. 3. № 4. P. 230–241. https://doi.org/10.1016/j.ijmyco.2014.09.002
  13. Performance Standards for Antimicrobial Susceptibility Testing. // Clinical and Laboratiry Standard Institute Wayne, V. 27(1). 17th Information Supplement.
  14. Myers A. // J. Biol. Educ. 1990. V. 24. № 2. P. 123–127. https://doi.org/10.1080/00219266.1990.9655123
  15. Salina E., Ryabova O., Kaprelyants A., Makarov V. // Antimicrob. Agents Chemother. 2014. V.58. № 1. P. 55–60. https://doi.org/10.1128/AAC.01308-13
  16. Hurst-Hess K.R., Saxena A., Rudra P., Yang Y., Ghosh P. // Mol. Cell. 2022. V.82. № 17. P. 3166–3177. https://doi.org/10.1016/j.molcel.2022.06.034
  17. Vesenbeckh S., Schönfeld N., Roth A., Bettermann G., Krieger D., Bauer T.T., Rüssmann H., Mauch H. // Eur. Respir. J. 2017. V. 49. № 5. P. 1700083. https://doi.org/10.1183/13993003.00083-2017

补充文件

附件文件
动作
1. JATS XML
下载
2.

下载 (27KB)
索引源数据
3.

下载 (61KB)
索引源数据

版权所有 © Б.А. Мартини, Е.Г. Салина, 2023